COVID-19 Seroprevalence in Cirrhotic Patients and Effect of COVID-19 Infection on Liver Cirrhosis by Clinical Form in the Postinfectious Period

dc.authorwosid kurt, enes ali/AAH-9029-2019
dc.authorwosid EŞKAZAN, TUĞÇE/ISU-9070-2023
dc.contributor.author Oenal, Ugur
dc.contributor.author Oezbey, Dogukan
dc.contributor.author Bakkaloglu, Oguz Kagan
dc.contributor.author Eskazan, Tugce
dc.contributor.author Kurt, Enes Ali
dc.contributor.author Hatemi, Ali Ibrahim
dc.contributor.author Sonsuz, Abdullah
dc.date.accessioned 2024-12-15T15:40:44Z
dc.date.available 2024-12-15T15:40:44Z
dc.date.issued 2024
dc.department Okan University en_US
dc.department-temp [Oenal, Ugur] Univ Hlth Sci Turkey, Istanbul Training & Res Hosp, Dept Gastroenterol, Istanbul, Turkiye; [Oezbey, Dogukan] Istanbul Okan Univ, Fac Med, Dept Microbiol, Istanbul, Turkiye; [Bakkaloglu, Oguz Kagan] Univ Hlth Sci Turkey, Kosuyolu Yuksek Ihtisas Training & Res Hosp, Clin Gastroenterol, Istanbul, Turkiye; [Eskazan, Tugce; Hatemi, Ali Ibrahim; Sonsuz, Abdullah] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Gastroenterol, Istanbul, Turkiye; [Kurt, Enes Ali] Kocaeli City Hosp, Clin Gastroenterol, Kocaeli, Turkiye; [Kocazeybek, Bekir] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Microbiol, Istanbul, Turkiye en_US
dc.description.abstract Introduction: There are very few studies demonstrating the seroprevalence of coronavirus disease-2019 (COVID-19) in patients with cirrhosis worldwide and in Turkey. This study aimed to investigate the seroprevalence of COVID-19 in patients with cirrhosis and its effect on liver cirrhosis by clinical form in the postinfectious period. Methods: The study included 174 patients with cirrhosis. Patients with COVID-19 were identified using anti-severe acute respiratory syndrome-coronavirus-2-immunoglobulin G (SARS-CoV-2-IgG) and COVID-19 polymerase chain reaction assays and were divided into symptomatic and asymptomatic groups. The last polyclinic records of the patients before infection or testing were determined as 1 st examination and the date of blood collection for anti-SARS-CoV-2-IgG was determined as the 2 nd examination. Examination findings and liver tests of the patients in both periods were recorded; Child-Pugh Score (CPS) and Model for End Stage Liver Disease (MELD)-Na scores were calculated. Additionally, patients were evaluated for newly developed hepatic decompensation. Results: The seropositivity of anti-SARS-CoV-2-IgG was detected in 35.6% of our patients, and the rate of those who had symptomatic COVID-19 infection was 23.6%, whereas the rate of those who had asymptomatic infection was 12%. There was no significant difference in liver tests, CPS, and MELD-Na scores before and after COVID-19 infection between symptomatic and asymptomatic patients, and new decompensation was found in 9.6% of patients with COVID-19 infection. Conclusion: The incidence of COVID-19 among patients with liver cirrhosis is notably high. Although high decompensation rates were reported in the acute phase of the disease, such rates were not observed in the postinfectious period. Ultimately, our results indicated no significant difference in the course of existing liver disease according to clinical form. en_US
dc.description.woscitationindex Emerging Sources Citation Index
dc.identifier.citationcount 0
dc.identifier.doi 10.4274/imj.galenos.2024.85461
dc.identifier.endpage 310 en_US
dc.identifier.issn 2619-9793
dc.identifier.issn 2148-094X
dc.identifier.issue 4 en_US
dc.identifier.scopusquality N/A
dc.identifier.startpage 304 en_US
dc.identifier.uri https://doi.org/10.4274/imj.galenos.2024.85461
dc.identifier.uri https://hdl.handle.net/20.500.14517/7510
dc.identifier.volume 25 en_US
dc.identifier.wos WOS:001367469500001
dc.language.iso en en_US
dc.publisher Galenos Publ House en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject COVID-19 en_US
dc.subject liver cirrhosis en_US
dc.subject seroprevalence en_US
dc.title COVID-19 Seroprevalence in Cirrhotic Patients and Effect of COVID-19 Infection on Liver Cirrhosis by Clinical Form in the Postinfectious Period en_US
dc.type Article en_US
dc.wos.citedbyCount 0

Files